Recombinant NGF is in phase 1 clinical trials for glaucoma (Clinicaltrials.gov identifier: NCT02855450) after a previous clinical trial showed that topical delivery was well tolerated by patients [44]. This evidence concerns the gene NGF and glaucoma.